145 related articles for article (PubMed ID: 32568510)
1. Discovery of Novel Antibiotics as Covalent Inhibitors of Fatty Acid Synthesis.
Wang J; Ye X; Yang X; Cai Y; Wang S; Tang J; Sachdeva M; Qian Y; Hu W; Leeds JA; Yuan Y
ACS Chem Biol; 2020 Jul; 15(7):1826-1834. PubMed ID: 32568510
[TBL] [Abstract][Full Text] [Related]
2. Design of Arylsulfonylhydrazones as Potential FabH Inhibitors: Synthesis, Antimicrobial Evaluation and Molecular Docking.
Fernandes TB; Segretti ND; Lourenço FR; Cândido TM; Baby AR; Barbosa EG; Parise-Filho R
Med Chem; 2021; 17(5):474-484. PubMed ID: 31763975
[TBL] [Abstract][Full Text] [Related]
3. A combine approach of chemical synthesis, biological evaluation and structural dynamics studies revealed thiazole substituted arylamine derivatives as potent FabH enzyme inhibitors.
Ahmad H; Ahmad F; Parveen S; Ahmad S; Azam SS; Hassan A
Bioorg Chem; 2020 Dec; 105():104426. PubMed ID: 33161255
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III (FabH) as potential antibacterial agents.
Shi L; Fang RQ; Zhu ZW; Yang Y; Cheng K; Zhong WQ; Zhu HL
Eur J Med Chem; 2010 Sep; 45(9):4358-64. PubMed ID: 20557983
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of C(7) modified chrysin derivatives designing to inhibit beta-ketoacyl-acyl carrier protein synthase III (FabH) as antibiotics.
Li HQ; Shi L; Li QS; Liu PG; Luo Y; Zhao J; Zhu HL
Bioorg Med Chem; 2009 Sep; 17(17):6264-9. PubMed ID: 19664929
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors.
Lv PC; Wang KR; Yang Y; Mao WJ; Chen J; Xiong J; Zhu HL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6750-4. PubMed ID: 19836235
[TBL] [Abstract][Full Text] [Related]
7. Novel FabH inhibitors: an updated article literature review (July 2012 to June 2013).
Song H; Ao GZ; Li HQ
Expert Opin Ther Pat; 2014 Jan; 24(1):19-27. PubMed ID: 24083428
[TBL] [Abstract][Full Text] [Related]
8. Discovery of vinylogous carbamates as a novel class of β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.
Li HQ; Luo Y; Zhu HL
Bioorg Med Chem; 2011 Aug; 19(15):4454-9. PubMed ID: 21742506
[TBL] [Abstract][Full Text] [Related]
9. Discovery of FabH/FabF inhibitors from natural products.
Young K; Jayasuriya H; Ondeyka JG; Herath K; Zhang C; Kodali S; Galgoci A; Painter R; Brown-Driver V; Yamamoto R; Silver LL; Zheng Y; Ventura JI; Sigmund J; Ha S; Basilio A; Vicente F; Tormo JR; Pelaez F; Youngman P; Cully D; Barrett JF; Schmatz D; Singh SB; Wang J
Antimicrob Agents Chemother; 2006 Feb; 50(2):519-26. PubMed ID: 16436705
[TBL] [Abstract][Full Text] [Related]
10. Purification, characterization, and identification of novel inhibitors of the beta-ketoacyl-acyl carrier protein synthase III (FabH) from Staphylococcus aureus.
He X; Reynolds KA
Antimicrob Agents Chemother; 2002 May; 46(5):1310-8. PubMed ID: 11959561
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and structure-activity relationships of pyrazole derivatives as potential FabH inhibitors.
Lv PC; Sun J; Luo Y; Yang Y; Zhu HL
Bioorg Med Chem Lett; 2010 Aug; 20(15):4657-60. PubMed ID: 20594840
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents.
Nie Z; Perretta C; Lu J; Su Y; Margosiak S; Gajiwala KS; Cortez J; Nikulin V; Yager KM; Appelt K; Chu S
J Med Chem; 2005 Mar; 48(5):1596-609. PubMed ID: 15743201
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping.
McKinney DC; Eyermann CJ; Gu RF; Hu J; Kazmirski SL; Lahiri SD; McKenzie AR; Shapiro AB; Breault G
ACS Infect Dis; 2016 Jul; 2(7):456-64. PubMed ID: 27626097
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antibacterial activity of cinnamaldehyde acylhydrazone with a 1,4-benzodioxan fragment as a novel class of potent β-ketoacyl-acyl carrier protein synthase III (FabH) inhibitor.
Song X; Yang Y; Zhao J; Chen Y
Chem Pharm Bull (Tokyo); 2014; 62(11):1110-8. PubMed ID: 25196128
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and antibacterial activities of 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiol derivatives containing Schiff base formation as FabH inhibitory.
Zhang F; Wen Q; Wang SF; Shahla Karim B; Yang YS; Liu JJ; Zhang WM; Zhu HL
Bioorg Med Chem Lett; 2014 Jan; 24(1):90-5. PubMed ID: 24332628
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, molecular modeling and biological evaluation of β-ketoacyl-acyl carrier protein synthase III (FabH) as novel antibacterial agents.
Zhang HJ; Zhu DD; Li ZL; Sun J; Zhu HL
Bioorg Med Chem; 2011 Aug; 19(15):4513-9. PubMed ID: 21741250
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel bacterial FabH inhibitors (Pyrazol-Benzimidazole amide derivatives): Design, synthesis, bioassay, molecular docking and crystal structure determination.
Wang YT; Shi TQ; Fu J; Zhu HL
Eur J Med Chem; 2019 Jun; 171():209-220. PubMed ID: 30925337
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening.
Zheng Z; Parsons JB; Tangallapally R; Zhang W; Rock CO; Lee RE
Bioorg Med Chem Lett; 2014 Jun; 24(11):2585-8. PubMed ID: 24755430
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of urea derivatives from o-hydroxybenzylamines and phenylisocyanate as potential FabH inhibitors.
Li ZL; Li QS; Zhang HJ; Hu Y; Zhu DD; Zhu HL
Bioorg Med Chem; 2011 Aug; 19(15):4413-20. PubMed ID: 21752655
[TBL] [Abstract][Full Text] [Related]
20. Study of Schiff-Base-Derived with Dioxygenated Rings and Nitrogen Heterocycle as Potential β-Ketoacyl-acyl Carrier Protein Synthase III (FabH) Inhibitors.
Zhou Y; Yang YS; Song XD; Lu L; Zhu HL
Chem Pharm Bull (Tokyo); 2017; 65(2):178-185. PubMed ID: 28154310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
